Small Molecule Oral Bioavailability Advantage
Small molecules offer oral dosing advantages over antibody biologics.
- Oral: Route of administration (placeholder note)
- <500 Da: Molecular weight (placeholder note)
- Favorable: BBB penetration (placeholder note)
- Daily: Dosing frequency (placeholder note)
Oral small molecule pharmacology
Placeholder: small molecule oral bioavailability and CNS penetration overview.
Blocking Tau Self-Aggregation
Inhibitor binds tau monomers to block self-aggregation.
- Repeat domain: Binding site (placeholder note)
- Aggregation block: Mechanism (placeholder note)
- Stabilized: Monomer pool (placeholder note)
- ThT fluorescence: Assay readout (placeholder note)
Tau self-aggregation blockade
Placeholder: mechanism of small molecule blocking tau monomer self-assembly.
Preventing Oligomer Formation
Inhibitor prevents formation of toxic tau oligomers.
- Reduced: Oligomer species (placeholder note)
- Lowered: Toxicity marker (placeholder note)
- Delayed: Time to oligomer (placeholder note)
- Native PAGE: Detection method (placeholder note)
Oligomer formation prevention
Placeholder: how the compound interrupts oligomer nucleation and growth.
Intracellular Target Engagement
Compound engages tau target inside neuronal cells.
- Cytosol: Cellular compartment (placeholder note)
- Confirmed: Target engagement (placeholder note)
- Neuronal line: Cell model (placeholder note)
- CETSA: Engagement assay (placeholder note)
Intracellular target engagement
Placeholder: intracellular delivery and tau target engagement details.
Combination With Antibody Approaches
Small molecule paired with anti-tau antibody for combination therapy.
- Anti-tau mAb: Combination partner (placeholder note)
- Intra + extra: Target compartments (placeholder note)
- Additive+: Expected synergy (placeholder note)
- Combo arm: Trial design (placeholder note)
Combination therapy rationale
Placeholder: rationale for combining small molecule with antibody therapy.
Placeholder: key insight on combination therapy synergy.